Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

URCC NCORP Research Base

Award Number: UG1CA189961
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2025
PERIOD OF PERFORMANCE END DATE: 07/31/2026

Group Awards By:

View Award Description

URCC NCORP Research Base - The University of Rochester Cancer Center (URCC) National Cancer Institute Community Oncology Research Program (NCORP) Research Base (RB) has over 35 years of experience conducting cancer control research (CCR) and cancer care delivery research (CCDR). The URCC NCORP RB vision is to help good people through lousy times when they experience cancer” by reducing cancer- and treatment-related morbidity stemming from toxicities and side effects. Since 2014, 35% (N=2831) of all accrual credits across the entire NCORP network resulted from enrollment of patients and survivors by our Community Affiliates on our 13 active URCC clinical trials. URCC and its Community Affiliates also enrolled 421 caregivers and more than 300 oncologists to our 13 active trials, as well as 1752 patients and survivors to our 29 local pilot studies. URCC successfully enrolled and randomized over 30 individual community oncology practices to cluster randomized trials. Our investigators and staff submitted 8 new concepts/grants, with 18 new concepts/grants currently in development, and 29 active pilot studies. The significant and innovative contribution of URCC research to scientific knowledge and clinical care is evidenced by 1) 197 published manuscripts, 2) 209 presented abstracts, 3) 25 podium presentations at ASCO, 4) 82 outstanding research awards to our investigators, and 5) 2215 investigators, clinicians and staff successfully trained to implement URCC NCORP RB protocols at community sites across the United States. Notable recognition of the significance of research conducted by the URCC RB and its investigators includes: 1) Best of JCO publications for 2017, 2) most cited article in JAMA Oncology for 2017, 3) one of the most significant advances in cancer research and care for 2018, 4) citation of our published research in virtually all existing oncology supportive care treatment guidelines, and 5) leadership by 5 of our RB Executive Committee members in the development of 4 oncology supportive care treatment guidelines. We accomplish our goal of reducing cancer- and treatment-related morbidity by working with cancer patients, survivors, and their caregivers from 592 community oncology practices across the United States to design and conduct CCR and CCDR, including translational outcomes, focused on symptom science. Our research develops and tests novel treatments for toxicities and side effects stemming from cancer and its treatments. We design and conduct phase I-III randomized clinical trials and longitudinal, prospective cohort studies. To meet its responsibilities as a RB and maintain its high level of productivity over the next funding period, the URCC RB will focus its resources and expertise on the following specific aims: Aim 1) to conduct CCR, Aim 2) to conduct CCDR, Aim 3) to conduct translational CCR, and Aim 4) to provide state-of-the-art training in clinical research methods for NCORP investigators and staff. With its proven record of productivity and innovation, the URCC NCORP RB is expertly positioned to continue its pioneering symptom science research in the NCORP Network.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	UNIVERSITY OF ROCHESTER	910 GENESEE ST	ROCHESTER	NY	14611	MONROE	USA	Cancer Control	001	11	7/15/2026	SUPPLEMENT FOR EXPANSION	$0
2026	2024	UNIVERSITY OF ROCHESTER	910 GENESEE ST	ROCHESTER	NY	14611	MONROE	USA	Cancer Control	000	11	7/15/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $5,649,423 )
2025	2025	UNIVERSITY OF ROCHESTER	910 GENESEE ST	ROCHESTER	NY	14611	MONROE	USA	Cancer Control	001	11	9/10/2025	SUPPLEMENT FOR EXPANSION	$5,649,423
2025	2024	UNIVERSITY OF ROCHESTER	910 GENESEE ST	ROCHESTER	NY	14611	MONROE	USA	Cancer Control	000	11	9/10/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $5,649,423

Issue Date FY: 2024 ( Subtotal = $6,309,234 )
2024	2024	UNIVERSITY OF ROCHESTER	910 GENESEE ST	ROCHESTER	NY	14611	MONROE	USA	Cancer Control	001	11	7/29/2024	NON-COMPETING CONTINUATION	$6,309,234
2024	2023	UNIVERSITY OF ROCHESTER	910 GENESEE ST	ROCHESTER	NY	14611	MONROE	USA	Cancer Control	000	10	5/27/2024	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $6,309,234

Issue Date FY: 2023 ( Subtotal = $6,108,842 )
2023	2023	UNIVERSITY OF ROCHESTER	910 GENESEE ST	ROCHESTER	NY	14611	MONROE	USA	Cancer Control	000	10	7/28/2023	NON-COMPETING CONTINUATION	$6,008,842
2023	2023	UNIVERSITY OF ROCHESTER	910 GENESEE ST	ROCHESTER	NY	14611	MONROE	USA	Cancer Control	001	10	9/18/2023	SUPPLEMENT FOR EXPANSION	$100,000
														Subtotal = $6,108,842

Issue Date FY: 2022 ( Subtotal = $5,877,231 )
2022	2022	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Control	002	9	9/13/2022	NON-COMPETING CONTINUATION	$385,054
2022	2022	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Control	001	9	7/29/2022	NON-COMPETING CONTINUATION	$5,492,177
2022	2021	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Control	000	8	5/19/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $5,877,231

Issue Date FY: 2021 ( Subtotal = $5,863,483 )
2021	2021	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Control	001	8	7/30/2021	NON-COMPETING CONTINUATION	$5,500,310
2021	2021	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Control	002	8	9/16/2021	NON-COMPETING CONTINUATION	$363,173
2021	2020	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Control	000	7	4/27/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $5,863,483

Issue Date FY: 2020 ( Subtotal = $6,180,306 )
2020	2020	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Control	004	7	9/8/2020	SUPPLEMENT FOR EXPANSION	$757,036
2020	2020	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Control	005	7	9/11/2020	NON-COMPETING CONTINUATION	$360,000
2020	2020	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Control	003	7	8/17/2020	NON-COMPETING CONTINUATION	$5,063,270
2020	2019	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Control	002	6	6/15/2020	COMPETING CONTINUATION	$0
2020	2019	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Control	001	6	2/19/2020	COMPETING CONTINUATION	$485,109
2020	2018	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Treatment Research	000	5	2/19/2020	NON-COMPETING CONTINUATION	-$485,109
														Subtotal = $6,180,306

Issue Date FY: 2019 ( Subtotal = $5,068,163 )
2019	2019	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Control	002	6	9/11/2019	COMPETING CONTINUATION	$350,000
2019	2019	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Control	001	6	8/16/2019	COMPETING CONTINUATION	$0
2019	2019	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Control	000	6	8/15/2019	COMPETING CONTINUATION	$4,718,163
														Subtotal = $5,068,163

Issue Date FY: 2018 ( Subtotal = $4,001,073 )
2018	2018	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Treatment Research	000	5	7/24/2018	NON-COMPETING CONTINUATION	$3,966,067
2018	2018	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Treatment Research	001	5	9/17/2018	NON-COMPETING CONTINUATION	$35,006
														Subtotal = $4,001,073

Issue Date FY: 2017 ( Subtotal = $3,781,235 )
2017	2017	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Treatment Research	000	4	7/27/2017	NON-COMPETING CONTINUATION	$3,781,235
														Subtotal = $3,781,235

Issue Date FY: 2016 ( Subtotal = $3,919,865 )
2016	2016	UNIVERSITY OF ROCHESTER	1325 MOUNT HOPE AVE, SUITE 260	ROCHESTER	NY	14642	MONROE	USA	Cancer Treatment Research	000	3	7/27/2016	NON-COMPETING CONTINUATION	$3,919,865
														Subtotal = $3,919,865

Issue Date FY: 2015 ( Subtotal = $5,267,174 )
2015	2015	UNIVERSITY OF ROCHESTER	1325 MOUNT HOPE AVE, SUITE 260	ROCHESTER	NY	14642	MONROE	USA	Cancer Treatment Research	003	2	9/11/2015	NON-COMPETING CONTINUATION	$938,572
2015	2015	UNIVERSITY OF ROCHESTER	1325 MOUNT HOPE AVE, SUITE 260	ROCHESTER	NY	14642	MONROE	USA	Cancer Treatment Research	001	2	8/20/2015	NON-COMPETING CONTINUATION	$408,273
2015	2015	UNIVERSITY OF ROCHESTER	1325 MOUNT HOPE AVE, SUITE 260	ROCHESTER	NY	14642	MONROE	USA	Cancer Treatment Research	000	2	7/29/2015	NON-COMPETING CONTINUATION	$3,730,599
2015	2015	UNIVERSITY OF ROCHESTER	1325 MOUNT HOPE AVE, SUITE 260	ROCHESTER	NY	14642	MONROE	USA	Cancer Treatment Research	002	2	9/1/2015	NON-COMPETING CONTINUATION	$189,730
														Subtotal = $5,267,174

Issue Date FY: 2014 ( Subtotal = $3,730,599 )
2014	2014	UNIVERSITY OF ROCHESTER	1325 MOUNT HOPE AVE, SUITE 260	ROCHESTER	NY	14642	MONROE	USA	Cancer Treatment Research	000	1	8/1/2014	NEW	$3,730,599
														Subtotal = $3,730,599

Grand Total All Awards = $61,756,628

Top

All Categories

About

Search

Reports

Data Submission

Award Information

URCC NCORP Research Base

Award Number: UG1CA189961

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2025

PERIOD OF PERFORMANCE END DATE: 07/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer